Skip to main content

ILLUMINA, INC.

corporate_fare Company Profile

ILLUMINA, INC.

ILMN·NASDAQ·Life Sciences·CIK 0001110803

Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis. The company offers instruments and consumables, including reagents, flow cells, and library preparation products. Its product portfolio includes whole-genome sequencing kits, designed to sequence entire genomes of varying sizes and complexities, and targeted resequencing kits, which sequence exomes, specific genes, RNA, or other genomic regions of interest. Illumina also provides services such as whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support. The company serves a diverse customer base, including genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical companies, biotechnology firms, commercial molecular diagnostic laboratories, and consumer genomics companies. Illumina markets and distributes its products directly to customers and through life-science distributors across the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company collaborates with Labcorp Holdings Inc. to develop oncology treatments using sequencing solutions and has a data partnership with the Center for Data-Driven Discovery in Biomedicine to advance research in pediatric cancer and rare diseases. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.

ILLUMINA, INC. (NASDAQ:ILMN) is a publicly traded company in the Life Sciences sector. Wiseek monitors ILMN SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • Roche Launches Axelios NGS System, Challenging Illumina's Core NovaSeq X Franchise
  • Illumina Appoints Eli Lilly's Chief Scientific Officer, Daniel Skovronsky, to Board of Directors
  • Director Keith Meister Sells Over $110 Million in Illumina Stock Near 52-Week High
  • Director-Affiliated Fund Files Intent to Sell $63.5M in Illumina Stock
  • Director Keith Meister Sells $84.8M in Illumina Stock and Terminates Equity Swaps

Financial Snapshot

Fiscal year ended December 28, 2025
Revenue
$4.34B
Net Income
$850M
Diluted EPS
$5.45
Op. Cash Flow
$1.08B
Free Cash Flow
$931M
Gross Profit
$2.87B
Operating Income
$807M
Cash & Equivalents
$1.42B
Debt / Equity
0.00×
Net Margin
19.6%
Shares Outstanding
153M sh
Source: 10-K · filed 2026-02-12 · accession 0001110803-26-000024
Browse all tickers starting with I →
$189.5 +0.03% today
52-week range · as of 2026-06-23 $88 – $189.5
Market cap
$28.67B
Volume
1.7M (0.9× avg)
3-mo avg 1.9M
Live data · 2026-07-28 08:57 UTC · Pre-market

show_chartPrice Chart

Loading chart...

feed ILMN - Latest Insights

ILMN
Jul 06, 2026, 7:19 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $189.30
Real-time Price: $189.50 info
Change: +$0.200 (+0.11%) info
Market Cap: $28.667B info
ILMN
Jun 23, 2026, 9:08 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $158.38
Real-time Price: $189.50 info
Change: +$31.12 (+20%) info
Market Cap: $28.667B info
ILMN
Jun 01, 2026, 6:04 PM EDT
Filing Type: 4
Importance Score:
8
Price at Filing: $164.40
Real-time Price: $189.50 info
Change: +$25.10 (+15%) info
Market Cap: $28.667B info
ILMN
May 29, 2026, 6:14 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $164.88
Real-time Price: $189.50 info
Change: +$24.62 (+15%) info
Market Cap: $28.667B info
ILMN
May 14, 2026, 7:21 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $144.85
Real-time Price: $189.50 info
Change: +$44.65 (+31%) info
Market Cap: $28.667B info
ILMN
May 01, 2026, 5:52 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $134.31
Real-time Price: $189.50 info
Change: +$55.19 (+41%) info
Market Cap: $28.667B info
ILMN
May 01, 2026, 4:06 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $135.83
Real-time Price: $189.50 info
Change: +$53.67 (+40%) info
Market Cap: $28.667B info
ILMN
Apr 30, 2026, 4:15 PM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $119.88
Real-time Price: $189.50 info
Change: +$69.63 (+58%) info
Market Cap: $28.667B info
ILMN
Apr 09, 2026, 4:16 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $123.67
Real-time Price: $189.50 info
Change: +$65.83 (+53%) info
Market Cap: $28.667B info
ILMN
Apr 02, 2026, 9:09 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $124.49
Real-time Price: $189.50 info
Change: +$65.01 (+52%) info
Market Cap: $28.667B info
ILMN
Feb 11, 2026, 7:32 PM EST
Filing Type: 10-K
Importance Score:
8
Price at Filing: $116.38
Real-time Price: $189.50 info
Change: +$73.12 (+63%) info
Market Cap: $28.667B info
ILMN
Feb 05, 2026, 4:09 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $128.80
Real-time Price: $189.50 info
Change: +$60.70 (+47%) info
Market Cap: $28.667B info
ILMN
Jan 30, 2026, 9:06 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $148.72
Real-time Price: $189.50 info
Change: +$40.78 (+27%) info
Market Cap: $28.667B info
ILMN
Jan 13, 2026, 9:11 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $146.64
Real-time Price: $189.50 info
Change: +$42.86 (+29%) info
Market Cap: $28.667B info
ILMN
Jan 08, 2026, 4:39 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $145.94
Real-time Price: $189.50 info
Change: +$43.56 (+30%) info
Market Cap: $28.667B info